{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:13:53Z","timestamp":1787026433965,"version":"build-2736575974"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"DOI":"10.3389\/fgene.2020.00584","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T07:12:25Z","timestamp":1591341145000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["HMTase Inhibitors as a Potential Epigenetic-Based Therapeutic Approach for Friedreich\u2019s Ataxia"],"prefix":"10.3389","volume":"11","author":[{"given":"Mursal","family":"Sherzai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adamo","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Kalef-Ezra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Al-Mahdawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Anjomani Virmouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/hmg\/ddm346","article-title":"The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues.","volume":"17","author":"Al-Mahdawi","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1242\/dmm.018952","article-title":"A novel GAA-repeat-expansion-based mouse model of Friedreich\u2019s ataxia.","volume":"8","author":"Anjomani Virmouni","year":"2015","journal-title":"Dis. Model. Mech."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107416","article-title":"Cellular, molecular and functional characterisation of YAC transgenic mouse models of Friedreich ataxia.","volume":"9","author":"Anjomani Virmouni","year":"2014","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/s40673-017-0062-x","article-title":"Friedreich Ataxia: current status and future prospects.","volume":"4","author":"Burk","year":"2017","journal-title":"Cereb. Ataxias"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/hmg\/6.11.1771","article-title":"Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes.","volume":"6","author":"Campuzano","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"B6","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich\u2019s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion.","volume":"271","author":"Campuzano","year":"1996","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1093\/hmg\/ddt115","article-title":"Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich\u2019s ataxia can be reduced upon HDAC inhibition by vitamin B3.","volume":"22","author":"Chan","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1093\/hmg\/8.12.2317","article-title":"Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene.","volume":"8","author":"Chiurazzi","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1093\/nar\/gkw107","article-title":"Reversal of epigenetic promoter silencing in Friedreich ataxia by a class I histone deacetylase inhibitor.","volume":"44","author":"Chutake","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/ana.23698","article-title":"Central role and mechanisms of beta-cell dysfunction and death in friedreich ataxia-associated diabetes.","volume":"72","author":"Cnop","year":"2012","journal-title":"Ann. Neurol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007914","article-title":"Epigenetic silencing in Friedreich ataxia is associated with depletion of CTCF (CCCTC-binding factor) and antisense transcription.","volume":"4","author":"De Biase","year":"2009","journal-title":"PLoS One"},{"key":"B12","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nchembio1006-512","article-title":"Breaking the silence in Friedreich\u2019s ataxia.","volume":"2","author":"Festenstein","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/jnc.12302","article-title":"Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich\u2019s ataxia.","volume":"126","author":"Gottesfeld","year":"2013","journal-title":"J. Neurochem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1093\/nar\/gkm271","article-title":"Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia.","volume":"35","author":"Greene","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nchembio815","article-title":"Histone deacetylase inhibitors reverse gene silencing in Friedreich\u2019s ataxia.","volume":"2","author":"Herman","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1111\/j.1742-4658.2006.05343.x","article-title":"The epigenetic magic of histone lysine methylation.","volume":"273","author":"Jenuwein","year":"2006","journal-title":"FEBS J."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007791.pub3","article-title":"Antioxidants and other pharmacological treatments for Friedreich ataxia.","volume":"4","author":"Kearney","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1101\/gr.229102","article-title":"The human genome browser at UCSC.","volume":"12","author":"Kent","year":"2002","journal-title":"Genome Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2011.01.010","article-title":"Friedreich\u2019s ataxia: pathology, pathogenesis, and molecular genetics.","volume":"303","author":"Koeppen","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1242\/jcs.01238","article-title":"Heterochromatin and tri-methylated lysine 20 of histone H4 in animals.","volume":"117","author":"Kourmouli","year":"2004","journal-title":"J. Cell. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function.","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.molcel.2007.01.017","article-title":"Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase.","volume":"25","author":"Kubicek","year":"2007","journal-title":"Mol. Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1093\/hmg\/ddw215","article-title":"Sustained expression of FMR1 mRNA from reactivated fragile X syndrome alleles after treatment with small molecules that prevent trimethylation of H3K27.","volume":"25","author":"Kumari","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"639.e","DOI":"10.1016\/j.ahj.2010.10.038","article-title":"Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA).","volume":"161","author":"Lagedrost","year":"2011","journal-title":"Am. Heart J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1001\/archneurol.2010.168","article-title":"A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia.","volume":"67","author":"Lynch","year":"2010","journal-title":"Arch. Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1212\/01.wnl.0000055872.50364.fc","article-title":"Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial.","volume":"60","author":"Mariotti","year":"2003","journal-title":"Neurology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/nrm1761","article-title":"The diverse functions of histone lysine methylation.","volume":"6","author":"Martin","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2015.00262","article-title":"Epigenetics and triplet-repeat neurological diseases.","volume":"6","author":"Nageshwaran","year":"2015","journal-title":"Front. Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00415-009-1002-3","article-title":"Friedreich ataxia: the clinical picture.","volume":"256","author":"Pandolfo","year":"2009","journal-title":"J. Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/s1097-2765(03)00477-5","article-title":"Partitioning and plasticity of repressive histone methylation states in mammalian chromatin.","volume":"12","author":"Peters","year":"2003","journal-title":"Mol. Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/emmm.201000064","article-title":"Long intronic GAA repeats causing Friedreich ataxia impede transcription elongation.","volume":"2","author":"Punga","year":"2010","journal-title":"EMBO Mol. Med."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/852080","article-title":"Epigenetics in Friedreich\u2019s ataxia: challenges and opportunities for therapy.","volume":"2013","author":"Sandi","year":"2013","journal-title":"Genet. Res. Int."},{"key":"B34","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.nbd.2011.02.016","article-title":"Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model.","volume":"42","author":"Sandi","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2014.00165","article-title":"Epigenetic-based therapies for Friedreich ataxia.","volume":"5","author":"Sandi","year":"","journal-title":"Front. Genet."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089488","article-title":"Generation and characterisation of Friedreich ataxia YG8R mouse fibroblast and neural stem cell models.","volume":"9","author":"Sandi","year":"","journal-title":"PLoS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nature01596","article-title":"DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing.","volume":"422","author":"Saveliev","year":"2003","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrneurol.2009.26","article-title":"Diagnosis and treatment of Friedreich ataxia: a European perspective.","volume":"5","author":"Schulz","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"B39","author":"Sherzai","year":"2018","journal-title":"Investigating Novel Therapies for Frieidriech\u2019s Ataxia."},{"key":"B40","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/ana.24260","article-title":"Epigenetic therapy for Friedreich ataxia.","volume":"76","author":"Soragni","year":"2014","journal-title":"Ann. Neurol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2019.04.004","article-title":"Lysine methylation regulates nervous system diseases.","volume":"76","author":"Wang","year":"2019","journal-title":"Neuropeptides"},{"key":"B42","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ymgme.2008.03.019","article-title":"Lateral-flow immunoassay for the frataxin protein in Friedreich\u2019s ataxia patients and carriers.","volume":"94","author":"Willis","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"B43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/jnc.12254","article-title":"Gene regulation and epigenetics in Friedreich\u2019s ataxia.","volume":"126","author":"Yandim","year":"2013","journal-title":"J. Neurochem."},{"key":"B44","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/jnen\/nly073","article-title":"Histone deacetylase inhibitors: a therapeutic key in neurological disorders?","volume":"77","author":"Ziemka-Nalecz","year":"2018","journal-title":"J. Neuropathol. Exp. Neurol."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fgene.2020.00584\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T07:12:29Z","timestamp":1591341149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fgene.2020.00584\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":44,"alternative-id":["10.3389\/fgene.2020.00584"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2020.00584","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"article-number":"584"}}